{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:51:24Z","timestamp":1791481884674,"version":"4.3.4"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118513","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:59:56Z","timestamp":1791039596000},"page":"118513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["The expression window as a safety parameter for mRNA medicines"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-4136","authenticated-orcid":false,"given":"Hidenori","family":"Tani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118513_b0005","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control Release"},{"key":"10.1016\/j.bcp.2026.118513_b0015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0020","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118513_b0025","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0030","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118513_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-025-02891-7","article-title":"RNA stability enhancers for durable base-modified mRNA therapeutics","author":"Jung","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","article-title":"Branched chemically modified poly(a) tails enhance the translation capacity of mRNA","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0045","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41587-024-02393-y","article-title":"Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/iub.70122","article-title":"Half-life as a therapeutic design axis: targeting short-lived lncRNAs with antisense oligonucleotides","volume":"78","author":"Tani","year":"2026","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bcp.2026.118513_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2026.195163","article-title":"Short-lived versus long-lived lncRNAs: RNA stability as a determinant of regulatory function","volume":"1869","author":"Tani","year":"2026","journal-title":"Biochim. Biophys. Acta, Gene Regul. Mech."},{"key":"10.1016\/j.bcp.2026.118513_b0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/cells15020156","article-title":"Chronic in vivo CRISPR-Cas genome editing: challenges, long-term safety, and outlook","volume":"15","author":"Bao","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118513_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114222","article-title":"Kinetics of RNA-LNP delivery and protein expression","volume":"197","author":"M\u00fcller","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bcp.2026.118513_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.apha.2026.05.007","article-title":"Transient T cell therapies","volume":"106","author":"Xiao","year":"2026","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118513_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2026.2614125","article-title":"Non-Viral CRISPR carriers: transient delivery with lasting effects","volume":"33","author":"Lummerstorfer","year":"2026","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bcp.2026.118513_b0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: the art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118513_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70038","article-title":"Advancing protein-coding RNA engineering: from structural refinement to biomedical implementation","volume":"20","author":"Lu","year":"2025","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.bcp.2026.118513_b0090","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2026.2661120","article-title":"Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: progress, evidence gaps, and translational pathways for durable and scalable immunization","volume":"22","author":"Okechukwu Paul-Chima","year":"2026","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bcp.2026.118513_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1758902","article-title":"Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases","volume":"17","author":"Ugwu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118513_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70146","article-title":"mRNA stability: an unresolved challenge for broad therapeutic applications","volume":"20","author":"Wang","year":"2025","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.bcp.2026.118513_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102737","article-title":"Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors","volume":"36","author":"Wang","year":"2025","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0110","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1021\/acs.jmedchem.6c00448","article-title":"From vaccines to therapeutics: the need for distinct mRNA-LNP design principles","volume":"69","author":"Wei","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118513_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114468","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: opportunities and challenges","volume":"189","author":"Fairman","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118513_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114374","volume":"189","author":"Yang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118513_b0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.xphs.2023.10.027","article-title":"Pharmacodynamic models of indirect effects and irreversible inactivation with turnover: applicability to mechanism-based modeling of gene silencing and targeted protein degradation","volume":"113","author":"Wang","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2026.118513_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13894","article-title":"Translational pharmacokinetic\/pharmacodynamic model for mRNA-0184, an investigational therapeutic for the treatment of heart failure","volume":"17","author":"Kaushal","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118513_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"Schwanh\u00e4usser","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0140","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.cell.2025.02.021","article-title":"Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions","volume":"188","author":"Li","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118513_b0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313107121","article-title":"Maximum entropy determination of mammalian proteome dynamics","volume":"121","author":"Dear","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2026.118513_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature11848","article-title":"Corrigendum: Global quantification of mammalian gene expression control","volume":"495","author":"Schwanh\u00e4usser","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1101\/gr.130559.111","article-title":"Genome-wide determination of RNA stability reveals hundreds of short-lived noncoding transcripts in mammals","volume":"22","author":"Tani","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.bcp.2026.118513_b0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s44211-024-00704-6","article-title":"Metabolic labeling of RNA using ribonucleoside analogs enables the evaluation of RNA synthesis and degradation rates","volume":"41","author":"Tani","year":"2025","journal-title":"Anal. Sci."},{"key":"10.1016\/j.bcp.2026.118513_b0165","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.bcp.2026.118513_b0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"9","author":"Ho\u0142ubowicz","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bcp.2026.118513_b0180","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nchembio.1793","article-title":"Small molecule-triggered Cas9 protein with improved genome-editing specificity","volume":"11","author":"Davis","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0185","doi-asserted-by":"crossref","first-page":"15334","DOI":"10.1038\/ncomms15334","article-title":"Hit and go CAS9 delivered through a lentiviral based self-limiting circuit","volume":"8","author":"Petris","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.07.050","article-title":"Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunization","author":"Froechlich","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0195","doi-asserted-by":"crossref","first-page":"27077","DOI":"10.1021\/acsnano.4c11652","article-title":"Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans","volume":"18","author":"Kent","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118513_b0200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17576180.2024.2360361","article-title":"Biodistribution of lipid nanoparticle, eGFP mRNA and translated protein following subcutaneous administration in mouse","volume":"16","author":"Sandelius","year":"2024","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bcp.2026.118513_b0205","article-title":"Differential clearance rate of proteins encoded on a self-amplifying mRNA COVID-19 vaccine in muscle and lymph nodes","volume":"42","author":"Kanechi","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bcp.2026.118513_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102948","article-title":"Biodistribution of mRNA vaccines in rats: Enrichment in injection site and lymph tissues and rapid clearance without tissue persistence","volume":"37","author":"Goody","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0215","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jhep.2025.06.018","article-title":"Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering","volume":"83","author":"Milani","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118513_b0220","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jcyt.2024.06.005","article-title":"Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products","volume":"26","author":"Chialastri","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bcp.2026.118513_b0225","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118513_b0230","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.ymthe.2025.12.041","article-title":"Transient muscle expression of mitoARCUS in mice leads to sustained reductions in pathogenic mtDNA and reduces fatigability","volume":"34","author":"Bacman","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0240","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2601283","article-title":"In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia","volume":"395","author":"Vafai","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0245","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0250","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/cells15070644","article-title":"CRISPR-Cas9 therapeutics in early clinical development: delivery and molecular diagnostics","volume":"15","author":"Rutkowska","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118513_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115346","article-title":"Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads","volume":"211","author":"Leandro","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2026.118513_b0260","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","article-title":"Treatment of a metabolic liver disease in mice with a transient prime editing approach","volume":"9","author":"Rothgangl","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bcp.2026.118513_b0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118513_b0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0280","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118513_b0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2026.118513_b0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0295","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf115","article-title":"First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer","volume":"30","author":"Sullivan","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2026.118513_b0300","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1158\/1078-0432.CCR-25-4643","article-title":"Lipid nanoparticle-encapsulated mRNA-2752 encoding human OX40L, IL-23, and IL-36\u03b3 plus durvalumab induces an immunostimulatory effect within the tumor microenvironment in patients with advanced solid tumors","volume":"32","author":"Sweis","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118513_b0305","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bcp.2026.118513_b0310","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/1078-0432.CCR-24-1983","article-title":"A phase I, first-in-human, dose-escalation, expansion trial of cytokine-encoding synthetic mRNA mixture alone or with cemiplimab in advanced solid tumors","volume":"31","author":"Bechter","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118513_b0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adm8451","article-title":"Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70","volume":"16","author":"Brook","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0320","doi-asserted-by":"crossref","unstructured":"Erratum for the Research Article \u201cAdjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70\u201d by B. Brook et al, Sci. Transl. Med. 16 (2024) eads5741. doi: 10.1126\/scitranslmed.ads5741.","DOI":"10.1126\/scitranslmed.ads5741"},{"key":"10.1016\/j.bcp.2026.118513_b0325","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","article-title":"mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions","volume":"33","author":"Nguyen","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0330","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118513_b0335","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0340","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.bcp.2026.118513_b0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-25-0663","article-title":"Targeted lipid nanoparticle delivery of FAP-CAR mRNA enables potent in vivo T-cell engineering against pancreatic tumors","volume":"14","author":"Bajbouj","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118513_b0350","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/biomedicines14061276","article-title":"In vivo mRNA-lipid nanoparticle CAR-T cell engineering: advances, challenges, and clinical translation","volume":"14","author":"Yadav","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118513_b0355","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.trecan.2026.01.007","article-title":"In vivo CAR T cell engineering: design principles and open questions","volume":"12","author":"Aalipour","year":"2026","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2026.118513_b0360","article-title":"mRNA lipid nanoparticles for cell engineering in vivo and in vitro: current applications and future directions","volume":"7","author":"Li","year":"2026","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.118513_b0365","article-title":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","volume":"29","author":"Inthanachai","year":"2026","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.bcp.2026.118513_b0370","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.stem.2010.08.012","article-title":"Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA","volume":"7","author":"Warren","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2026.118513_b0375","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s42003-024-06328-w","article-title":"In vivo cyclic overexpression of Yamanaka factors restricted to neurons reverses age-associated phenotypes and enhances memory performance","volume":"7","author":"Ant\u00f3n-Fern\u00e1ndez","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2026.100378","article-title":"Oxidative stress drives liver failure during in vivo partial reprogramming","volume":"49","author":"Eom","year":"2026","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bcp.2026.118513_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114569","article-title":"Hepatocyte-specific partial cellular reprogramming via selective OSK mRNA lipid nanoparticle attenuates liver fibrosis","volume":"390","author":"Zhang","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0390","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/1521-4141(2000)30:8<2226::AID-IMMU2226>3.0.CO;2-5","article-title":"Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin","volume":"30","author":"Wang","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2026.118513_b0395","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0400","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.celrep.2018.08.049","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"24","author":"An","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118513_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101557","article-title":"Reversing PAI-1 deficiency in blood using mRNA lipid nanoparticles","volume":"33","author":"Ferraresso","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2026.118513_b0410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/acs.molpharmaceut.5c00774","article-title":"mRNA-based therapeutics: advances in drug delivery, comparative innovations, and biomedical applications","volume":"23","author":"Joshi","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.118513_b0415","doi-asserted-by":"crossref","first-page":"984","DOI":"10.25122\/jml-2025-0180","article-title":"Ocular gene therapy as a sustained drug delivery system: pharmacokinetic and genokinetic perspectives","volume":"18","author":"Leferman","year":"2025","journal-title":"J. Med. Life"},{"key":"10.1016\/j.bcp.2026.118513_b0420","article-title":"Engineering the poly(a) tail for therapeutic mRNA: from expression control to manufacturing robustness","volume":"14","author":"Zhang","year":"2026","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0425","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1021\/acs.chemrev.5c00347","article-title":"Beyond the sequence: chemical and topological design and innovations in mRNA therapeutics","volume":"126","author":"Liu","year":"2026","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2026.118513_b0430","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118513_b0435","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0440","article-title":"Divergent delivery and expression kinetics of lipid and polymeric nanoparticles across mRNA modalities","volume":"12","author":"Casmil","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bcp.2026.118513_b0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2024.07.078","article-title":"Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity","volume":"374","author":"Bathula","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0450","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948220","article-title":"Codon bias confers stability to human mRNAs","volume":"20","author":"Hia","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bcp.2026.118513_b0455","doi-asserted-by":"crossref","DOI":"10.1126\/science.adw0288","article-title":"Human DHX29 detects nonoptimal codon usage to regulate mRNA stability","volume":"392","author":"Hia","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118513_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114098","article-title":"Attenuating ribosome load improves protein output from mRNA by limiting translation-dependent mRNA decay","volume":"43","author":"Bicknell","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118513_b0465","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nm1398","article-title":"Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer","volume":"12","author":"Brown","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102609","article-title":"MicroRNA-responsive ON-OFF hybrid mRNA switch for precise protein expression control","volume":"36","author":"Masaki","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0475","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1039\/D5SC07482G","article-title":"Time-ordered-expression mRNA (TOE mRNA) for melanoma RNA vaccines","volume":"17","author":"Zhang","year":"2026","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bcp.2026.118513_b0480","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchembio.598","article-title":"Small-molecule displacement of a cryptic degron causes conditional protein degradation","volume":"7","author":"Bonger","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0485","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0490","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1038\/ncomms14370","article-title":"Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization","volume":"8","author":"Senturk","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0495","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.2224","article-title":"Multidimensional chemical control of CRISPR-Cas9","volume":"13","author":"Maji","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0500","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.3390\/molecules27196266","article-title":"Small molecules for enhancing the precision and safety of genome editing","volume":"27","author":"Shin","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118513_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102640","article-title":"Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader","volume":"36","author":"Khajanchi","year":"2025","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0510","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","article-title":"A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules","volume":"126","author":"Banaszynski","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118513_b0515","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm.1754","article-title":"Chemical control of protein stability and function in living mice","volume":"14","author":"Banaszynski","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118513_b0520","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/s41467-026-73681-1","article-title":"The benchmarking and application of tag-degraders in vivo to validate therapeutic targets","volume":"17","author":"Magtoto","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0525","doi-asserted-by":"crossref","unstructured":"G.M.P. Giordano Attianese, S. Shui, E. Cribioli, M. Triboulet, L. Scheller, M. Hafezi, P. Reichenbach, P. Gainza, S. Georgeon, B.E. Correia, M. Irving, Dual ON\/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs, Proc. Natl. Acad. Sci. U.S.A. 121 (2024) e2405085121. doi: 10.1073\/pnas.2405085121.","DOI":"10.1073\/pnas.2405085121"},{"key":"10.1016\/j.bcp.2026.118513_b0530","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1016\/j.ymthe.2025.04.031","article-title":"IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15","volume":"33","author":"Burga","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0535","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70181","article-title":"Pharmacokinetics and pharmacodynamics of KT-474, a novel selective Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) degrader, in healthy adults","volume":"18","author":"Agarwal","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118513_b0540","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2026.118513_b0545","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03022-6","article-title":"In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery","author":"Jozi\u0107","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118513_b0555","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol","volume":"16","author":"Johansson","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114047","article-title":"The kinetics of endosomal disruption reveal differences in lipid nanoparticle induced cellular toxicity","volume":"386","author":"Bates","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0565","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2012.12.029","article-title":"Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format","volume":"166","author":"Phua","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0570","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.115049","article-title":"Trace PEG-lipid engineering unlocks superior mRNA delivery via albumin-mediated liver targeting and enhanced endosomal escape","volume":"396","author":"Fang","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118513_b0590","doi-asserted-by":"crossref","unstructured":"B.L. Mui, Y.K. Tam, M. Jayaraman, S.M. Ansell, X. Du, Y.Y.C. Tam, P.J. Lin, S. Chen, J.K. Narayanannair, K.G. Rajeev, M. Manoharan, A. Akinc, M.A. Maier, P. Cullis, T.D. Madden, M.J. Hope, Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles, Mol. Ther. Nucl. Acids 2 (2013) e139, doi:10.1038\/mtna.2013.66.","DOI":"10.1038\/mtna.2013.66"},{"key":"10.1016\/j.bcp.2026.118513_b0595","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118513_b0600","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41467-025-68103-7","article-title":"Multiplexed lipid nanoparticle barcoding reveals tissue-dynamic kinetic insights and enriched cellular tropism in hepatic zones","volume":"17","author":"Moore","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0605","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10928-026-10052-9","article-title":"Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets","volume":"53","author":"Miyazawa","year":"2026","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.bcp.2026.118513_b0610","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/psp4.70131","article-title":"The Impact of QSP modeling on the design and optimization of gene therapy approaches","volume":"14","author":"Rayad","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118513_b0615","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0968-0004(00)89102-1","article-title":"AU-rich elements: characterization and importance in mRNA degradation","volume":"20","author":"Chen","year":"1995","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.bcp.2026.118513_b0620","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1128\/MCB.19.6.4311","article-title":"Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA","volume":"19","author":"Lai","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0625","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature07117","article-title":"A discontinuous hammerhead ribozyme embedded in a mammalian messenger RNA","volume":"454","author":"Martick","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0630","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1038\/s41467-019-12334-y","article-title":"Massively parallel RNA device engineering in mammalian cells with RNA-Seq","volume":"10","author":"Xiang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0635","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118513_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102485","article-title":"Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3' UTR via HuR anchorage","volume":"36","author":"Ma","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0645","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1126\/science.adp8179","article-title":"Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies","volume":"386","author":"Lindley","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118513_b0650","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1038\/s41467-026-72025-3","article-title":"Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0655","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-025-08842-1","article-title":"Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines","volume":"641","author":"Krawczyk","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118513_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151436","article-title":"A reversible small-molecule-switchable self-amplifying RNA expression platform","volume":"355","author":"Lin","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118513_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102729","article-title":"Antisense oligonucleotide-based switches for conditional translation of synthetic mRNA","volume":"36","author":"Combes","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118513_b0670","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1038\/s41467-025-60392-2","article-title":"Split RNA switch orchestrates pre- and post-translational control to enable cell type-specific gene expression","volume":"16","author":"Abe","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0675","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1208\/s12248-026-01273-4","article-title":"Whole-body pharmacokinetics of ionizable lipid, mRNA, and the expressed antibody following intravenous administration of mRNA-loaded lipid nanoparticles","volume":"28","author":"Tiwari","year":"2026","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118513_b0680","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17576180.2026.2664198","article-title":"Comparative assessment of RT-dPCR and RT-qPCR for RNA quantification in IgG mRNA-lipid nanoparticle bioanalysis","volume":"18","author":"Jiang","year":"2026","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bcp.2026.118513_b0685","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41467-025-57446-w","article-title":"Monitoring mRNA vaccine antigen expression in vivo using PET\/CT","volume":"16","author":"Blizard","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118513_b0690","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1021\/jacs.5c07897","article-title":"mRNA-based FRET-FLIM imaging platform for quantifying lipid nanoparticle endosomal escape and membrane damage","volume":"147","author":"Fang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118513_b0695","doi-asserted-by":"crossref","first-page":"20299","DOI":"10.1038\/s41598-019-56869-y","article-title":"Short-lived long noncoding RNAs as surrogate indicators for chemical stress in HepG2 cells and their degradation by nuclear RNases","volume":"9","author":"Tani","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:05:24Z","timestamp":1791479124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":139,"alternative-id":["S0006295226008555"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118513","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The expression window as a safety parameter for mRNA medicines","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118513"}}